Your browser doesn't support javascript.
loading
Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy.
Curtis, Susanna A; Raisa, Balbuena-Merle; Roberts, John D; Hendrickson, Jeanne E; Starrels, Joanna; Lesley, Devine; Michelle, DeVeaux; Daniel, Zelterman; Brandow, Amanda M.
Afiliação
  • Curtis SA; Yale Cancer Center, Yale School of Medicine, CT, United States. Electronic address: scurtis@montefiore.org.
  • Raisa BM; Yale Cancer Center, Yale School of Medicine, CT, United States.
  • Roberts JD; Yale Cancer Center, Yale School of Medicine, CT, United States.
  • Hendrickson JE; Yale Cancer Center, Yale School of Medicine, CT, United States.
  • Starrels J; Division of General Internal Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, United States.
  • Lesley D; Yale Cancer Center, Yale School of Medicine, CT, United States.
  • Michelle D; Regeneron Pharmaceuticals, NY, United States.
  • Daniel Z; Yale School of Public Health, CT United States.
  • Brandow AM; Medical College of Wisconsin, WI, United States.
Transfus Apher Sci ; 61(2): 103304, 2022 Apr.
Article em En | MEDLINE | ID: mdl-34782244
ABSTRACT

BACKGROUND:

Chronic red blood cell transfusions reduce acute care utilization for sickle cell disease (SCD) pain. However, little is known about whether chronic transfusions treat or prevent the development of non-crisis pain. We investigated patient-report of pain in adults with SCD receiving chronic exchange transfusions (CET) compared to adults not on CET with similar disease characteristics. STUDY METHOD AND

DESIGN:

Eleven participants receiving chronic exchange transfusion (CET) for at least one year were compared to 33 participants not receiving CET. Participants completed validated patient-reported outcomes regarding pain impact and quality of life at regularly scheduled visits or before CET. One year of health care utilization and opioid prescriptions were examined.

RESULTS:

After 11 propensity matching was performed for age, genotype, WBC and neutrophil counts, patients on CET had lower Pain Impact scores (-5.1, p = 0.03) and higher Neuropathic (7.4, p < 0.001) and Nociceptive Pain Quality (3.7, p < 0.001) scores, all indicating worse pain. However, CET was associated with a reduction in annual all cause admissions (-3.1, p < 0.001), length of stay (-2.1 days, p < 0.001) and ED visits (-2.7, p < 0.001). CET was not associated with differences in opioids dispensed.

CONCLUSIONS:

After adjusting for disease characteristics, CET was associated with worse pain impact and neuropathic and nociceptive pain quality, lower health care utilization and with similar levels of opioids dispensed. This data suggest that CET may reduce hospitalizations for acute pain but may not adequately treat nociceptive or neuropathic pain in SCD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Nociceptiva / Doença Enxerto-Hospedeiro / Anemia Falciforme Limite: Adult / Humans Idioma: En Revista: Transfus Apher Sci Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Nociceptiva / Doença Enxerto-Hospedeiro / Anemia Falciforme Limite: Adult / Humans Idioma: En Revista: Transfus Apher Sci Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article